title: [Sentinel node procedure and endometrial cancer: senti-endo results].
abstract: Based on two randomized trials and a meta-analysis, the recommendations of the National Cancer Institute (INCa) have validated the absence of systematic pelvic lymphadenectomy for patients with endometrial cancer at low risk (type 1 histology stage IA grade 1-2) and intermediate (type 1 histology stage IA grade 3 and IB grade 1-2) but without taking into account the contribution of the sentinel node (SN) procedure. The senti-endo trial assessing the role of the SN procedure in patients with early stages endometrial cancer showed that the detection rate by hemi-pelvis right and left were 77 and 76%, respectively. The detection rate per patient was 89%. Among patients with at least a SN detected, the detection was unilateral in 34 cases (31%) and bilateral in 77 cases (69%). Of the 111 patients with at least a SN detected, 19 had lymph node metastases (17%). Considering the hemi-pelvis right and left as a unit, no false negative case was observed, hence the sensitivity and NPV was 100%. Considering the NPV per patient, three false negative cases were observed. Among the 57 patients at low risk, six (11%) had lymph node metastases on SN with negative non sentinel nodes. Of the 33 patients at intermediate risk, five (15%) had lymph node metastases on SN with negative non sentinel nodes. Senti-endo results emphasize the contribution of the SN procedure to assess the nodal status in patients with low or intermediate risk group raising the issue on new definition of the recommendations of INCa.
authors.affiliation: AP-HP, hôpital Tenon, université Pierre-et-Marie-Curie - Paris-VI, service de gynécologie-obstétrique, CancerEst, Paris, France. emile.darai@tnn.aphp.fr
authors.forename: Emile
authors.initials: E
authors.lastname: Daraï
authors.forename: Chrysoula
authors.initials: C
authors.lastname: Zacharopoulou
authors.forename: Cyril
authors.initials: C
authors.lastname: Touboul
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Chéreau
authors.forename: Marcos
authors.initials: M
authors.lastname: Ballester
mesh_terms: D016889:Endometrial Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery; D005260:Female; D006801:Humans; D008197:Lymph Node Excision / Q000379:methods*; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008207:Lymphatic Metastasis / Q000473:pathology; D008279:Magnetic Resonance Imaging; D009367:Neoplasm Staging / Q000379:methods; D010388:Pelvis; D011237:Predictive Value of Tests; D011379:Prognosis; D011877:Radionuclide Imaging; D012306:Risk; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*